Rocket Pharmaceuticals Inc (NASDAQ:RCKT) Expected to Earn Q1 2021 Earnings of ($0.70) Per Share

Rocket Pharmaceuticals Inc (NASDAQ:RCKT) – Investment analysts at Piper Jaffray Companies issued their Q1 2021 earnings per share (EPS) estimates for Rocket Pharmaceuticals in a report issued on Thursday, November 7th. Piper Jaffray Companies analyst T. Van. Buren anticipates that the biotechnology company will earn ($0.70) per share for the quarter. Piper Jaffray Companies has a “Overweight” rating on the stock. Piper Jaffray Companies also issued estimates for Rocket Pharmaceuticals’ Q2 2021 earnings at ($0.75) EPS and Q3 2021 earnings at ($0.80) EPS.

Other analysts have also issued research reports about the company. Chardan Capital began coverage on Rocket Pharmaceuticals in a research note on Tuesday. They issued a “buy” rating and a $30.00 price objective on the stock. Cowen restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Thursday. Oppenheimer dropped their price objective on Rocket Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. William Blair restated a “buy” rating on shares of Rocket Pharmaceuticals in a research note on Tuesday, September 10th. Finally, Zacks Investment Research downgraded Rocket Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $28.33.

NASDAQ:RCKT opened at $16.36 on Friday. The company has a quick ratio of 17.48, a current ratio of 17.48 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average price is $13.02 and its two-hundred day moving average price is $14.19. The firm has a market capitalization of $729.55 million, a price-to-earnings ratio of -8.66 and a beta of 2.74. Rocket Pharmaceuticals has a 12-month low of $10.75 and a 12-month high of $20.79.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.11.

Several institutional investors have recently bought and sold shares of RCKT. BlackRock Inc. grew its position in Rocket Pharmaceuticals by 21.1% during the second quarter. BlackRock Inc. now owns 2,563,600 shares of the biotechnology company’s stock worth $38,455,000 after buying an additional 447,257 shares in the last quarter. Cormorant Asset Management LP grew its position in Rocket Pharmaceuticals by 22.0% during the second quarter. Cormorant Asset Management LP now owns 2,074,595 shares of the biotechnology company’s stock worth $31,119,000 after buying an additional 374,595 shares in the last quarter. Perceptive Advisors LLC grew its position in Rocket Pharmaceuticals by 331.6% during the second quarter. Perceptive Advisors LLC now owns 1,977,412 shares of the biotechnology company’s stock worth $29,661,000 after buying an additional 1,519,239 shares in the last quarter. Vanguard Group Inc. grew its position in Rocket Pharmaceuticals by 18.6% during the second quarter. Vanguard Group Inc. now owns 1,502,349 shares of the biotechnology company’s stock worth $22,536,000 after buying an additional 235,411 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its position in Rocket Pharmaceuticals by 24.7% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,172,946 shares of the biotechnology company’s stock worth $17,594,000 after buying an additional 232,542 shares in the last quarter. 96.72% of the stock is currently owned by institutional investors.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has clinical-stage lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; and leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction It also has additional pre-clinical stage LVV programs include pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia; and infantile malignant osteopetrosis, a genetic disorder characterized by increased bone density and bone mass secondary to impaired bone resorption.

Read More: How dollar cost averaging works

Earnings History and Estimates for Rocket Pharmaceuticals (NASDAQ:RCKT)

Receive News & Ratings for Rocket Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rocket Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.